Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective
Open Access
- 28 September 2012
- journal article
- Published by Springer Nature in Health Economics Review
- Vol. 2 (1) , 20
Abstract
To obtain detailed real-life data on costs and dosing patterns in the utilisation of the TNF inhibitors adalimumab, etanercept, and infliximab in patients treated in Switzerland.Keywords
This publication has 19 references indexed in Scilit:
- 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritisAnnals of the Rheumatic Diseases, 2011
- Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritisAmerican Journal of Health-System Pharmacy, 2010
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals of the Rheumatic Diseases, 2010
- A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overviewCanadian Medical Association Journal, 2009
- Treatment recommendations for psoriatic arthritisAnnals of the Rheumatic Diseases, 2009
- Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritisCurrent Medical Research and Opinion, 2008
- Rheumatoid ArthritisDrugs, 2008
- Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims dataCurrent Medical Research and Opinion, 2007
- International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 2003
- Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sourcesAnnals of the Rheumatic Diseases, 2003